How Sol-Gel is Responding to Covid-19
LEARN MORE

Pipeline

A diverse pipeline of topical skin medications

EPSOLAY®

(benzoyl peroxide) Cream, 5%
Papulopustular Rosacea

research preclinical phaseⅠⅠ phaseⅠⅠⅠ NDA
submission
FDA
Approved
Galderma
Partnership

TWYNEO®

(benzoyl peroxide and tretinoin) Cream, 3%/0.1%
Acne Vulgaris

research preclinical phaseⅠⅠ phaseⅠⅠⅠ NDA
submission
FDA
Approved
Galderma
Partnership

SGT-210 (erlotinib)

Palmoplantar Keratoderma

research preclinical phaseⅠⅠ phaseⅠⅠⅠ NDA
submission
FDA
Approved
 

SGT-310 (tapinarof)

Psoriasis & Other Dermatological Indications

research preclinical phaseⅠⅠ phaseⅠⅠⅠ NDA
submission
FDA
Approved
 

SGT-510 (roflumilast)

Psoriasis & Other Dermatological Indications

research preclinical phaseⅠⅠ phaseⅠⅠⅠ NDA
submission
FDA
Approved
 

*The safety and efficacy of these products have not been established.

Our Microencapsulation Technology

EPSOLAY®

Epsolay is an investigational topical cream containing benzoyl peroxide, 5%, for the treatment of papulopustular rosacea. Epsolay utilizes a patented technology process that is designed to slowly release benzoyl peroxide over time to the skin. The FDA has accepted our NDA for Epsolay. PDUFA goal date was set for April 26, 2021. Awaiting FDA’s pre-approval inspection. If approved, Epsolay has the potential to be the first single-active benzoyl peroxide approved by the FDA as a prescription drug product.

LEARN MORE

The safety and efficacy of Epsolay have not been established.
Epsolay is a registered trademark of Sol-Gel Technologies, Ltd.

Not an actual patient – actor portrayal

TWYNEO®

TWYNEO® (benzoyl peroxide and tretinoin) Cream, 3%/0.1%, now approved by the FDA, is an an antibiotic-free, fixed-dose combination of benzoyl peroxide, 3%, and tretinoin, 0.1%, cream for the treatment of acne vulgaris, using our proprietary drug-delivery technology. It is the first acne treatment on the US market that contains a fixed-dose combination of benzoyl peroxide and tretinoin. Tretinoin and benzoyl peroxide are each approved as single-agent products for the treatment of acne. They are frequently prescribed together, however, they have not yet been marketed as a combination product because benzoyl peroxide causes degradation of tretinoin when combined in the same formulation. In TWYNEO® (benzoyl peroxide and tretinoin) Cream, 3%/0.1%, each ingredient is encapsulated in a silica shell, which is designed to release the ingredients slowly over time. The FDA has approved the product on July 26, 2021.

Not an actual patient – actor portrayal

SGT-210

SGT-210 (erlotinib) is an investigational, topical epidermal growth factor receptor inhibitor in development for the treatment of palmoplantar keratoderma (PPK), a group of skin conditions characterized by thickening of the skin on the hands and soles of the feet, as well as basal cell carcinoma and squamous cell carcinoma, collectively referred to as non-melanoma skin cancer.


SGT-310 and SGT-510

We also intend to develop SGT-310 (tapinorof), an aryl hydrocarbon receptor (AhR) agonist, and SGT-510 (roflumilast), a phosphodiesterase 4 (PDE4) inhibitor, each as potential treatments for psoriasis and other dermatological indications.

The safety and efficacy of these products have not been established.